Erratum to 'How we treat medulloblastoma in adults': [ESMO Open Volume 6, Issue 4, August 2021, 100173].
作者信息
Franceschi E, Seidel C, Sahm F, Pajtler K W, Hau P
机构信息
Department of Medical Oncology, Azienda USL/IRCCS Institute of Neurological Sciences, Bologna, Italy.
Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany.
出版信息
ESMO Open. 2021 Dec;6(6):100327. doi: 10.1016/j.esmoop.2021.100327. Epub 2021 Nov 12.
Abstract
摘要
相似文献
1
Erratum to 'How we treat medulloblastoma in adults': [ESMO Open Volume 6, Issue 4, August 2021, 100173].《成人髓母细胞瘤的治疗方法》勘误：[《ESMO开放杂志》第6卷，第4期，2021年8月，100173]。
ESMO Open. 2021 Dec;6(6):100327. doi: 10.1016/j.esmoop.2021.100327. Epub 2021 Nov 12.
2
Erratum to 'How we treat primary central nervous system lymphoma': [ESMO Open Volume 6, Issue 4, August 2021, 100213].《“我们如何治疗原发性中枢神经系统淋巴瘤”的勘误》：[《ESMO开放》第6卷，第4期，2021年8月，100213]
ESMO Open. 2021 Dec;6(6):100326. doi: 10.1016/j.esmoop.2021.100326. Epub 2021 Nov 10.
3
Erratum to 'FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?': [ESMO Open Volume 5, Issue 5, 2020, e000633].《局部晚期十二指肠腺癌的FOLFIRINOX或FOLFOXIRI方案：我们是否错失良机？》勘误：[《ESMO开放杂志》第5卷，第5期，2020年，e000633]
ESMO Open. 2021 Jun;6(3):100138. doi: 10.1016/j.esmoop.2021.100138.
4
Erratum to 'Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis': [ESMO Open Volume 6, Issue 2, April 2021, 100088].《HER2 阳性乳腺癌患者的辅助内分泌治疗：系统评价与荟萃分析》勘误：[《ESMO 开放》第 6 卷，第 2 期，2021 年 4 月，100088]
ESMO Open. 2021 Jun;6(3):100158. doi: 10.1016/j.esmoop.2021.100158.
5
Erratum to 'Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival': [ESMO Open Volume 7, Issue 2, April 2022, 100409].《转移性乳腺癌治疗的重大进展：拓展治疗选择即延长生存期》勘误：[《ESMO 开放》第 7 卷，第 2 期，2022 年 4 月，100409]
ESMO Open. 2022 Jun;7(3):100472. doi: 10.1016/j.esmoop.2022.100472. Epub 2022 Apr 7.
6
Erratum to 'Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial': [ESMO Open Volume 6, Issue 3, June 2021, 100101].《阿维鲁单抗联合阿昔替尼对比舒尼替尼治疗肉瘤样肾细胞癌的疗效及相关性分析：一项随机临床试验的事后分析》勘误：[《ESMO Open》第6卷，第3期，2021年6月，100101]
ESMO Open. 2021 Aug;6(4):100177. doi: 10.1016/j.esmoop.2021.100177. Epub 2021 Jun 8.
7
Erratum to 'Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome': [ESMO Open Volume 6, Issue 1, February 2021, 100005].《“COVID-19 之前及期间癌症患者血液学和生化参数的纵向特征揭示与预后相关的特征”勘误》：[《ESMO 开放》第 6 卷，第 1 期，2021 年 2 月，100005]
ESMO Open. 2021 Apr;6(2):100056. doi: 10.1016/j.esmoop.2021.100056. Epub 2021 Jan 28.
8
Erratum to 'Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario': [ESMO Open Volume 7, Issue 2, April 2022, 100406].《“评估2019冠状病毒病对意大利肺癌患者诊断治疗途径延误的影响（COVID-DELAY研究）：来自真实世界的更少病例和更高分期”的勘误》：[《欧洲肿瘤内科学会开放》第7卷，第2期，2022年4月，100406]
ESMO Open. 2022 Apr;7(2):100471. doi: 10.1016/j.esmoop.2022.100471. Epub 2022 Apr 1.
9
Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447].《GATTO研究的勘误：一项Ib期研究，将抗TA-MUC1抗体Gatipotuzumab与抗EGFR抗体Tomuzotuximab联合用于难治性实体瘤患者》：[《ESMO Open》第7卷，第2期，2022年4月，100447]
ESMO Open. 2022 Aug;7(4):100549. doi: 10.1016/j.esmoop.2022.100549. Epub 2022 Jul 13.
10
Corrigendum to 'How I treat medullary thyroid cancer': [ESMO Open Volume 6, Issue 3, June 2021, 100183].《我如何治疗甲状腺髓样癌》勘误：[《ESMO 开放杂志》第 6 卷，第 3 期，2021 年 6 月，100183]
ESMO Open. 2022 Jun;7(3):100516. doi: 10.1016/j.esmoop.2022.100516. Epub 2022 Jun 7.
Zotero 插件